SU056 treatments demonstrate antileukemia efficacy both in vitro and in vivo. (A-B) Cell viability was determined using MTS assay in Jurkat (A) and Molt4 (B) cells treated with SU056 at various concentrations for 48 hours. (C-D) Quantification of cell apoptosis in Jurkat (C) and Molt4 (D) cells treated with SU056 for 48 hours. (E) Percentages of GFP⁺ leukemia cells in peripheral blood were measured via flow cytometry on day 14. (F-G) GFP⁺ leukemia cells in the BM (F) and spleen (G) were quantified via flow cytometry on day 16. (H) Survival curves were plotted using the Kaplan-Meier curves (n = 8; long-rank test). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001.